| Investor | Value | Of portfolio | Shares | Change | Quarter |
|---|---|---|---|---|---|
| ARK Investment Management · Cathie Wood | $76.0M | 0.49% | 506.42K | +4.1% | Q2 2026 |
| Bridgewater Associates · Ray Dalio | $636.7K | 0.00% | 4.24K | −68% | Q2 2026 |
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
| Member | Buys | Sells | Est. net | Last move |
|---|---|---|---|---|
| Sheldon Whitehouse Sen. RI | 1 | +$8.0K | Bought Nov 21, 25 |
| Traded | Member | Owner | Type | Amount | Filed | Report |
|---|---|---|---|---|---|---|
| Nov 21, 25 | Sheldon Whitehouse Sen. RI | Self | Buy | $1,001 - $15,000 | Dec 1, 25 (10d) | Report |
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Sep 20, 2026 | Mignone Roberto A.Director | — | 264 | — |
| Sep 16, 2026 | Hidalgo Medina ManuelDirector | — | 232 | — |
| Sep 15, 2026 | Azar Alex M IiDirector | Sale at price 175.00 per share. | 826 | $144.55K |
| Sep 15, 2026 | Krognes Steve EDirector | Sale at price 174.46 - 177.48 per share. | 6.7K | $1.17M |
| Sep 15, 2026 | Tariq MusaDirector | Sale at price 175.00 per share. | 116 | $20.30K |
| Sep 14, 2026 | Tariq MusaDirector | — | 249 | — |
| Sep 14, 2026 | Chudova DaryaChief Technology Officer | Sale at price 178.00 per share. | 7.7K | $1.38M |
| Sep 10, 2026 | Azar Alex M IiDirector | — | 1.7K | — |
| Sep 10, 2026 | Kalia KumudChief Technology Officer | Sale at price 158.05 per share. | 4K | $632.19K |
| Aug 25, 2026 | Eltoukhy Helmy AChief Executive Officer | Stock Gift at price 0.00 per share. | 30K | — |
| Aug 20, 2026 | Talasaz AmiraliChief Executive Officer | Sale at price 168.20 - 170.29 per share. | 37.5K | $6.34M |
| Aug 20, 2026 | Mignone Roberto A.Director | — | 264 | — |
| Aug 16, 2026 | Hidalgo Medina ManuelDirector | — | 232 | — |
| Aug 16, 2026 | Tariq MusaDirector | Sale at price 156.45 per share. | 116 | $18.15K |
| Aug 13, 2026 | Tariq MusaDirector | — | 250 | — |
| Aug 11, 2026 | Monroe Terilyn JOfficer | Sale at price 163.41 - 167.92 per share. | 46.3K | $7.65M |
| Aug 11, 2026 | Monroe Terilyn JOfficer | Conversion of Exercise of derivative security at price 20.14 - 28.61 per share. | 46.3K | $1.05M |
| Aug 10, 2026 | Eltoukhy Helmy AChief Executive Officer | Stock Gift at price 0.00 per share. | 35K | — |
| Aug 9, 2026 | Talasaz AmiraliChief Executive Officer | Stock Gift at price 0.00 per share. | 75K | — |
| Aug 9, 2026 | Saia John GomesOfficer | Stock Gift at price 0.00 per share. | 800 | — |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 11.7 | -17.7 | -1.6 | -5.7 | 48.9 | 15.7 | 8.0 | -1.8 | 12.2 | -8.7 | +59.4% | ||
| 2025 | 53.8 | -9.4 | 0.1 | 10.9 | -14.0 | 28.1 | -21.3 | 64.5 | -7.3 | 48.9 | 16.6 | -5.8 | +234.3% |
| 2024 | -18.9 | -13.4 | 8.6 | -12.7 | 50.6 | 6.6 | 21.6 | -27.2 | -10.3 | -4.6 | 62.8 | -14.2 | +12.9% |
| 2023 | 15.6 | -1.7 | -24.1 | -3.8 | 30.0 | 22.1 | 9.0 | 0.2 | -24.2 | -12.7 | -2.7 | 7.5 | −0.6% |
| 2022 | -30.5 | -4.7 | -0.0 | -6.9 | -33.6 | -1.6 | 24.4 | -0.2 | 7.5 | -8.0 | 5.7 | -48.0 | −72.8% |
| 2021 | 20.7 | -5.4 | 3.7 | 4.1 | -21.9 | 0.1 | -11.6 | 15.9 | -1.8 | -6.6 | -10.0 | -4.9 | −22.4% |
| 2020 | -2.7 | 14.4 | -20.0 | 10.6 | 17.5 | -10.2 | 5.0 | 12.1 | 17.0 | -4.6 | 13.6 | 6.4 | +64.9% |
| 2019 | 7.3 | 65.2 | 15.1 | -14.6 | 17.4 | 12.3 | 8.9 | -6.9 | -27.1 | 8.9 | 11.8 | 0.6 | +107.9% |
| 2018 | 6.7 | 5.2 | +12.3% |
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company offers Guardant360 CDx test, a liquid biopsy test for tumor mutation profiling; Guardant360 Liquid test, which measures 740+ genes and supports all guideline-recommended biomarkers; Guardant Reveal test, a blood test that utilizes circulating tumor DNA to detect cancer at the molecular level; and Guardant360 Tissue test, a molecular profiling test for tumor tissue that provides genomic, transcriptomic, and epigenomic insights. It also provides Shield blood test for colorectal cancer screening in adults. In addition, the company offers GuardantINFINITY test that provides insights into the complexities of tumor molecular profiles and immune response to advance cancer research and therapy development; GuardantOMNI test covers 500 genes, including genes associated with homologous recombination repair deficiency and biomarkers for immuno-oncology applications; GuardantINFORM, which provides longitudinal biological insight into tumor evolution alongside longitudinal clinical outcomes; and GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies. Further, it provides Smart Platform, which delivers multiomic insights leveraging genomic, epigenomic, and RNA-based data that are scalable from research to the clinic. Additionally, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kit fulfillment and delivery of Shield screening tests. It has a strategic collaboration with Nuvalent, Inc. for oncology drug development. The company was incorporated in 2011 and is headquartered in Palo Alto, California.
Buy / hold / sell counts